Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis by Barra, Fabio et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iemt20
Expert Opinion on Drug Metabolism & Toxicology
ISSN: 1742-5255 (Print) 1744-7607 (Online) Journal homepage: http://www.tandfonline.com/loi/iemt20
Current understanding on pharmacokinetics,
clinical efficacy and safety of progestins for
treating pain associated to endometriosis
Fabio Barra, Carolina Scala & Simone Ferrero
To cite this article: Fabio Barra, Carolina Scala & Simone Ferrero (2018): Current
understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating
pain associated to endometriosis, Expert Opinion on Drug Metabolism & Toxicology, DOI:
10.1080/17425255.2018.1461840
To link to this article:  https://doi.org/10.1080/17425255.2018.1461840
Accepted author version posted online: 04
Apr 2018.
Submit your article to this journal 
View related articles 
View Crossmark data
Ac
ce
pte
d M
an
us
cri
pt
Publisher: Taylor & Francis 
Journal: Expert Opinion on Drug Metabolism & Toxicology 
DOI: 10.1080/17425255.2018.1461840 
Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for 
treating pain associated to endometriosis 
 
Fabio Barra 1,2, Carolina Scala 1,2, Simone Ferrero 1,2 
 
Institutions: 
1 Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi 
10, 16132 Genoa, Italy 
2 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child 
Health (DiNOGMI), University of Genoa, Italy 
 
Corresponding Author:  
Simone Ferrero MD, PhD; Academic Unit of Obstetrics and Gynecology, IRCCS AOU San 
Martino – IST, Largo R. Benzi 10, 16132 Genoa, Italy  
Telephone 01139 010 511525   
Mobile 01139 3477211682 
Fax 01139 010511525    
E-mail: simone.ferrero@unige.it 
 
 
Funding 
This paper was not funded.  
 
Declaration of interest:  
The authors have no relevant affiliations or financial involvement with any organization or entity 
with a financial interest in or financial conflict with the subject matter or materials discussed in the 
manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert 
testimony, grants or patents received or pending, or royalties. Peer reviewers on this manuscript 
have no relevant financial or other relationships to disclose 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Abstract  
Introduction 
Endometriosis is a chronic estrogen and progestogen responsive inflammatory disease associated 
with pain symptoms and infertility. The medical therapy of endometriosis aims to induce 
decidualization within the hormonally dependent ectopic endometrium, and it is often administered 
to ameliorate women’ pain symptoms or to prevent post-surgical disease recurrence. A variety of 
progestins have been used in monotherapy for the medical management of women with 
endometriosis.  
Areas covered 
This review aims to offer the reader a complete overview of pharmacokinetic (PK) and clinical 
efficacy of progestins for the treatment of endometriosis. 
Expert opinion 
Each progestin has a distinct PK parameters and pharmacodynamics affinity not only for 
progesterone receptor, but also for other steroid receptors, such as estrogen, androgen, and 
glucocorticoid. Moreover, progestins can also be delivered in different formulations. All these 
characteristics influence their final biological effect. Randomized, controlled, non-blinded studies 
support the use of oral progestin-only treatment for pelvic pain associated with endometriosis. 
Currently, the only two progestins approved by Food and Drug Administration (FDA) for the 
treatment of endometriosis are norethindrone acetate (NETA) and depot medroxyprogesterone 
acetate (DMPA). 
 
Keywords: Endometriosis, progestins, medical therapy, norethindrone, dienogest, depot 
medroxyprogesterone, LNG-IUD 
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Article Highlights 
• Progestins have been increasingly and successfully employed as monotherapy for the 
treatment of endometriosis related pain symptoms, being efficacious and well tolerated in 
several randomized, controlled, non-blinded studies; 
• Progestins have good a long-term tolerability profile. However, the main drug-related AEs 
are spotting and breakthrough bleeding, depression, breast tenderness and fluid retention; 
• Currently only norethindrone acetate (NETA) and depot medroxyprogesterone acetate 
(DMPA) as monotherapy have been approved by the Food and Drug Administration (FDA) 
for the treatment of endometriosis; 
• NETA is one of the most studied progestin for the treatment of endometriosis. Its good 
safety-profile and efficacy in improving endometriosis-related pain do NETA a suitable 
medical option among first-line therapies; 
• One of the best long-term medical treatment for endometriosis is the LNG-IUD. In 
comparison with the systemic administration, its local release of progestin has similar or 
improved efficacy, particularly evident on the local target organ, with reduced systemic 
AEs. 
• Further studies are needed to clarify the effect of long-term treatment with progestins on 
bone mineral density (BMD). 
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1.0 Introduction  
Endometriosis is a chronic estrogen and progestogen responsive inflammatory condition defined by 
the presence of glands and stroma, which affects about 6-10% of women of reproductive age [1]. 
Endometriosis is distinguished in three different phenotypes: ovarian endometrioma, superficial 
peritoneal endometriosis, and deep infiltrating endometriosis (DIE). Clinically, endometriosis can 
cause both pain symptoms (dysmenorrhea, deep dyspareunia, chronic pelvic pain and dyschezia) 
and infertility [2]. The surgical excision of endometriotic implants improves pain symptoms, but it 
may be associated with intestinal, urological and vascular complications. Furthermore, 
endometriosis-related pain may recur after surgery and patients may not accept a second operation. 
In addition, some patients desire to delay or avoid surgery preferring a long-term medical therapy to 
control their symptoms [3].  
Medical treatment of endometriosis acts inducing decidualization and eventually atrophy within the 
hormonally dependent ectopic endometrium [4]. It aims to ameliorate pain symptoms as long-term 
therapy in women who do not undergo surgery. Moreover, it is controversial its role in preventing 
the postsurgical recurrences of implants, which has been demonstrated in short-term studies for 
ovarian endometriomas [5]. Differently, hormonal therapies used to treat endometriosis have no 
role in improving endometriosis-related infertility [6]. The choice of most appropriate therapy is 
based on intensity of pain, age, desire to conceive, cost, route of administration and impact of the 
endometriosis on work capacity, sexual function and quality of life (QoL) of each patient [7].  
Traditionally combined oral contraceptive (COC) pills have been the first-line treatment for patients 
with endometriosis, but currently progestins are increasingly and successfully employed as 
monotherapy, being efficacious and well tolerated [8, 9, 10]. This review aims to summarize the 
pharmacokinetic (PK) and the clinical efficacy of progestins available for the medical treatment of 
endometriosis. 
A literature search was performed to find all the published studies evaluating PK and clinical 
efficacy of progestins for the treatment of endometriosis from inception until December 2017. The 
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following electronic databases were used: Medline, PubMed, Embase, Science Citation Index via 
Web of Science, and the Cochrane Library. The following search terms were used: ‘endometriosis’ 
alone or in combination with ‘progestin’, ‘medical therapy’, ‘pregnanes’, ‘estranes’, ‘gonanes’ 
‘norethindrone’, ‘cyproterone’, ‘desogestrel,’etonogestrel’ ‘medroxyprogesterone’, ‘dienogest’ 
‘levonorgestrel-intrauterine device’. All pertinent articles were carefully evaluated and their 
reference lists were examined in order to identify other manuscripts that could be included in the 
present drug evaluation. 
 
2.0 Medical therapy of endometriosis 
Circulating estrogens stimulate the growth of endometriotic implants. Furthermore, it known that 
estradiol (E2) is produced locally by the overexpression of aromatase in the endometriotic implants 
of all phenotypes of endometriosis [11, 12, 13]. Moreover, also the presence of estrogen and 
progesterone receptors has been well documented in the three types of endometriosis [14], 
including DIE [15]. In addition, endometriotic cells produce several prostaglandins that are 
involved in the inflammatory state, pelvic pain and neo-angiogenesis of implants [16]. 
The currently available medical therapies for endometriosis primarily exert their action by 
suppressing ovulation and inducing a relatively hypoestrogenic state. Hormonal therapies, 
particularly progestins and COCs, have been repeatedly demonstrated to be safe, well tolerated and 
effective in clinical trials, and currently they represent the first-line medical treatment for women 
affected by this disease [17, 18]. Laparoscopic confirmation of the diagnosis of endometriosis may 
be advisable prior to administering second-line hormonal treatments, such as gonadotropin-
releasing hormone agonists (GnRH-a), which induce suppression of the hypothalamic-pituitary-
ovary axis [19]. If all these treatments are ineffective, experimental therapies, such aromatase 
inhibitors, may be considered [20]. 
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3.0 Progestins 
Progestogens acts on endometriotic implants exerting systemic and local effect, so that they aim to 
induce anovulation and hypoestrogenism causing decidualization and acyclicity of both normal and 
ectopic endometrium. Firstly, on hypothalamus, they reduce the frequency and increase the 
amplitude of gonadotropin-releasing hormone (GnRH) pulsatile release, thus leading to a reduction 
in the secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH). Therefore, the 
continuous use of progestogens causes suppression of ovarian steroidogenesis with anovulation 
decreasing serum levels of endogenous ovarian steroids. Moreover, they can locally inhibit 
inflammatory pathways and response, and provoke apoptosis of endometriotic cells [21]. In 
particular, it has been demonstrated that they can reduce interleukin (IL)-6, IL-8, and monocyte 
chemotactic protein (MCP)-1 secretions of endometriotic stromal cells, and cellular proliferation 
stimulated by tumor necrosis factor-α (TNF-α) [22, 23]. Furthermore, they reduce oxidative stress, 
inhibits angiogenesis as well as suppress expression of matrix metalloproteinases, which may 
contribute to the development and to the growth of endometriotic lesions (Figure 1) [12, 24]. All 
these direct effects and the concomitant hypoestrogenic environment associated with 
hyperprogestogenic systemic status may be responsible for the decidual transformation and 
consequent atrophy of the normal endometrium and ectopic implants [25]. 
Progestins, synthetic progestogens, are a chemically various group of compounds with a 
multiplicity of actions on progesterone receptor as well as estrogen, androgen, mineralocorticoid, 
glucocorticoid and other receptors. These compounds can be divided in three classes (Figure 2): 
progesterone derivatives (pregnanes), testosterone derivatives (estranes and gonanes) and 
spironolactone derivatives. A great variety of progestins, available in different and multiple 
formulations (Table 1), have been employed in the management of endometriosis in association 
with estrogens or alone [17, 26]. However, only progestins belonging to progesterone and 
testosterone derivatives have been used as monotherapy; while no spironolactone derivate has been 
tested in this setting. 
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The drugs have good tolerability profile. The main progestin-related adverse effects (AEs) 
experienced by patients are spotting and breakthrough bleeding, depression, breast tenderness and 
fluid retention. These AEs are also the major cause of discontinuation of treatment in these patients 
[27].  
Currently, among the progestins, only depot medroxyprogesterone acetate (DMPA) and 
norethindrone acetate (NETA) as monotherapy are approved by the Food and Drug Administration 
(FDA) for the treatment of endometriosis. 
 
 
3.1 Norethindrone acetate 
NETA (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate) is a synthetic, orally active 
progestin, derivative of 19-nor-testosterone (estrane, testosterone derivate). It has also weak 
estrogenic and androgenic properties [28]. 
3.1.1 Pharmacokinetic 
After oral administration, NETA (5 mg) is completely and rapidly deacetylated to norethindrone 
(NET) [29], which generally achieves maximum plasma concentration (Cmax) within 2 hours [30]. 
Its volume of distribution (VD) is about 4 L/kg, and it is 61% bound to serum albumin and 38% to 
sex hormone-binding globulin (SHBG). NET undergoes extensive hepatic biotransformation, 
primarily via reduction, followed by sulfate and glucuronide conjugation [31]. A small extent 
(0.20–0.33%) is converted by hepatic aromatase to ethinylestradiol (EE) [32]. The majority of 
plasmatic NET metabolites are sulfates, whereas glucuronides account for most of the urinary 
metabolites. NET mean total clearance (Cl) is approximately 0.4 L/hr/kg, and its metabolites are 
excreted in both urine and feces. Its terminal elimination half-life (t1/2) after a single oral dose is 
approximately 9 hours [31]. 
3.1.2 Clinical efficacy and safety 
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NETA is one of the most studied progestin for the treatment of endometriosis. In a randomized 
controlled trial (RTC), Vercellini et al. compared NETA (2.5 mg/day) with a COC regimen (EE 
0.01 mg + cyproterone acetate [CPA] 3 mg). The regimens were administered to 90 patients with 
symptomatic rectovaginal endometriosis. After 12 months, 73% of women in the NETA group were 
satisfied or very satisfied with treatment compared to 62% in the COC group (p = 0.37). Both 
treatments were equally effective in controlling pain symptoms and in reducing the size of the 
lesions assessed by TVS. Only five of the 45 women (9%) receiving NETA withdrew because of 
adverse effects (AEs) or persistent pain. The most frequently reported AEs in the NETA group were 
weight gain (27%) and decreased libido (9%) [33]. 
In a patient-preference parallel cohort study, continuous NETA (2.5 mg/day) was compared to 
surgery for the treatment of 154 patients with endometriosis-associated deep dyspareunia. In the 
surgery group (51 women), there was a marked improvement of dyspareunia, followed by partial 
recurrence of pain. In the NETA group (103 patients), pain relief was more gradual but progressive 
throughout the whole study period. Moreover, at the end of 12 months of follow-up, patients treated 
with NETA had a greater increase in intercourse frequency per month and had higher satisfaction 
(59% versus 43%). At 1-year follow-up, NETA had better outcomes than surgery in patients 
without DIE implants. Moreover, among patients with rectovaginal nodules, NETA showed 
comparable efficacy [34].  
Ferrero et al. investigated the efficacy of NETA for the treatment of pain and gastrointestinal 
symptoms in 40 women with colorectal endometriosis. This drug improved the intensity of deep 
dyspareunia, dyschezia and chronic pelvic pain, causing also the disappearance of symptoms related 
to the menstrual cycle. Moreover, it improved the severity of diarrhea, intestinal cramping and 
passage of mucus of these patients. On the other hand, its administration did not have a significant 
effect on constipation, abdominal bloating and feeling of incomplete evacuation after bowel 
movements. 32 (80%) women completed the study protocol, and the most common causes for 
interruption of treatment were worsening of constipation (n=3) and breakthrough bleeding (n=2). 
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The presence of intestinal endometriosis was confirmed in all patients who underwent surgery after 
the end of the treatment (n=13) [35]. 
A prospective, non-randomized, open-label study including 40 patients compared the changes in the 
volume of ovarian endometriotic cysts during 6-month treatment with NETA alone or combined 
with letrozole. Both treatments significantly decreased the volume of endometriomas; however, the 
decrease in the volume of endometriomas was higher in patients receiving the double-drug regimen 
than in those receiving NETA alone. The improvement in pain symptoms was similar in the two 
study groups. After the discontinuation of treatment, the volume of endometriotic cysts 
progressively increased and after 6 months it was similar to baseline in both study groups [36].  
In a long-term retrospective cohort study, 103 women with pain symptoms caused by rectovaginal 
endometriosis received NETA (2.5 mg/day up to 5 mg/day) for a 5-year therapy. Overall, 68.8% 
(42/61) of the women who completed the study were satisfied or very satisfied of NETA. Intensity 
of chronic pelvic pain and deep dyspareunia significantly decreased during treatment (p<.001 
versus baseline at 1- and 5-year). Dyschezia improved after 1-year compared to baseline (p=0.008) 
but it remained stable between first and second year (p=.409). Regarding size of implants, a 
reduction was observed at RMI in 55.9% (33/59) of women whereas a volumetric increase was 
observed in 11.9% of them (7/59) [37]. 
Recently, a patient preference prospective study demonstrated that NETA (2.5 mg/day) and a 91-
day extended-cycle COC (LNG plus EE 150/30 μg for 84 days and EE 10 μg for 7 days) have 
similar efficacy in treating pain symptoms related to endometriosis [38]. However, the extended-
cycle OC caused more unscheduled bleeding than NETA. 
Regarding safety-profile of NETA by evaluating the largest series available, among 271 patients the 
most common AEs experienced were weight gain (n=78, 28.8%), breakthrough bleeding (n=45, 
16.6%) and decreased libido (n=34, 12.5%) [6, 37, 39]. 
 
3.2 Cyproterone acetate 
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Cyproterone acetate (CPA, 6-Chloro-17α-hydroxy-1α,2α-methylenepregna-4,6-diene-3,20-dione 
acetate) is a synthetic steroid with antiandrogenic and progestinic proprieties (gonane, testosterone 
derivate) [40].  
3.2.1 Pharmacokinetic 
An intra-individual comparison study investigated the PK of CPA in six healthy women. Following 
oral administration of CPA-14C (2 mg), administered together with EE (50 pg), the maximum 
radioactivity in the total plasma volume was 2.0% of the dose. After 24 hours from its 
administration, 0.63% of the dose was detected in plasma, and the mean CPA-14C AUC was 26.7%. 
Disposition phase 1 was recognizable in the period between the Cmax and 12-16 hours after 
administration and passed with a t1/2 of 3-4 hours. In the period from 24 hours to day 3, the plasma 
concentration fell more slowly with a t1/2 of approximately 2 days [41]. In terms of plasma protein 
binding, CPA does not bind to SHBG or transcortin and is instead bound exclusively to albumin 
(93%) [42]. Thus, the terminal t1/2 of the total activity in plasma was determined as 1.7 days. CPA is 
almost completely metabolized via the cytochrome P450 isoenzyme CYP3A4, and its main 
metabolite is 15β-OH-CPA. In the study, its quotient of the elimination urine: faces was 0.5, with 
mean balances of 88% of the dose [41].  
3.2.2 Clinical efficacy and safety 
The use of CPA as monotherapy for the treatment of endometriosis has been investigated only in 
two studies. A pilot study by Moran et al. on seven women with surgically confirmed endometriosis 
evaluated the effectiveness of 6-month cyclical CPA (10 mg/day for 20 days, followed by 10 days 
without medication). The regimen improved dysmenorrhea in all the patients. At second-look 
laparoscopy, five patients (71%) had minimal endometriosis and two patients (29%) had no 
evidence of the disease [43].  
In a RCT, Vercellini et al. compared the efficacy and safety of low-dose CPA (12.5 mg/day) with a 
COC (EE 0.02 mg + desogestrel, DSG, 0.15 mg) in 90 women with recurrent moderate or severe 
endometriosis-related pelvic pain persisting after conservative surgery. At 6 months, 73% of 
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women who received CPA were satisfied or very satisfied (versus 67% of those receiving the COC; 
p=.65). Dysmenorrhea, deep dyspareunia, and non-menstrual pelvic pain scores were substantially 
reduced and significant improvements in QoL, psychiatric profile, and sexual satisfaction were 
observed in both treatment groups. Amenorrhea was reached in approximately 66% of women who 
received CPA and in about 50% of those who received COC. The withdrawal rate was similar in 
both groups (9 and 6 patients, respectively) [44]. 
Regarding safety profile of CPA as monotherapy for endometriosis, in the study by Vercellini et al. 
the main AEs experienced were bloating or swelling (n=14, 32%), spotting (n=12, 28%) and weight 
gain (n=8, 19%). The mean weight gain was 2.4 kg (versus 2.2 kg for COC) whereas there were no 
significant changes in serum lipid profiles. Moreover, the main AEs that caused CPA 
discontinuation were bloating (n=1), decreased libido (n=1), depression (n=1), and headache (n=1) 
[44].  
  
 
3.3 Desogestrel 
DSG (3-Deketo-11-methylene-17α-ethynyl-18-methyl-19-nortestosterone) is a third-generation 19-
nortestosterone derivative progestin (gonane, testosterone derivate) [45]. It is commonly used in 
various formulations for hormonal contraception including combinations with EE, progestin-only 
pill and subdermal implants [46]. 
3.3.1 Pharmacokinetic 
After oral administration, the DNG bioavailability is about 76%. It is rapidly absorbed and 
converted to 3-keto DSG (or etonogestrel, ETN) [47] by hydroxylation and subsequent oxidation. 
The conversion occurs fairly rapidly in vivo, with prevalent hepatic metabolism by cytochrome 
(CYP) P450 and a moderate contribution of the intestinal mucosa [48]. The bio-activation of DSG 
to ETN has a wide variation between patients, ranging from 40 to 113% of the dose [49]. ETN is 
responsible for the pharmacological effect, exerting much stronger progestogen activity than the 
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parent compound. During multiple oral administration of DSG (75 µg), the Cmax of ETN is 
approximately 640 pg/ml and it is achieved within 2 h. Its steady state is reached after 4 days. ETN 
is largely bound to serum albumin (58%) and SHBG (38%), and 3.5% remains unbound and 
bioactive. ETN is subsequently metabolized to polar derivatives in the liver. The ETN t1/2 is about 
30 h, with no difference between single and multiple oral doses [50]; the drug is predominantly 
(~60%) excreted via urine, and only about 35% is excreted via feces [51].  
3.3.2 Clinical efficacy and safety 
In the first study reported, continuous oral DSG (75 μg/day) was compared to COC (EE 20 μg + 
DSG 150 μg /day) for the treatment of 40 patients with stage I-II endometriosis. At 6-months of 
follow-up, pelvic pain improved without difference between the two study arms. Moreover, 
breakthrough bleeding (20%) was the main AE reported in the DSG group [52]. 
In an open-label prospective trial, the combinatory regimen of oral DSG and an aromatase inhibitor 
(letrozole, 2.5 mg/day) was studied in the 6-month treatment of 12 patients with persistent 
endometriosis-related (stage IV) pelvic pain, not responding to previous surgical and medical 
therapies. None of the patients completed the treatment course because of the development of 
functional ovarian cysts; the median length of treatment of 84 days (range 56–112). This AE should 
be ascribed to the aromatase inhibi or. In fact, this drug blocks the conversion of androgens to 
estrogens in ovarian granulosa cells, with a consequent reduction of the negative feedback at the 
pituitary-hypothalamus level, and therefore, increase of serum FSH levels that promoted the ovarian 
follicles growth. Although the authors chose to combine letrozole with DSG to inhibit effectively 
ovulation, the progestin did not prevent the development of functional ovarian cysts. During the 
treatment period, all the patients had significant improvements in dyspareunia and chronic pelvic 
pain. The main AEs in both groups were abnormal bleeding (75%), weight gain (50%) and 
abdominal bloating (42%) [53].  
In 2014, a patient preference trial compared the contraceptive vaginal ring (EE 15 μg + ENG 120 
μg), administered cyclically, with oral DSG (75 μg/day) for the treatment of women with 
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symptomatic rectovaginal endometriosis. In this trial, 60 women received DSG and 83 women the 
vaginal ring. At the end of the 12-months of treatment, the rate of satisfied women was higher in the 
DSG group (61.7% versus 36.1%). There was no difference in the withdrawal rate between the two 
study groups. Moreover, the two treatments caused a similar disease volume size reduction. 
Interestingly, gastrointestinal symptoms, chronic pelvic pain, and deep dyspareunia improved more 
in patients receiving DSG [54].  
In another patient preference study, oral DSG (75 μg/day) and cyclic COC (EE 20 μg + DSG 150 
μg) were administered to 74 women with symptomatic rectovaginal implants and migraine without 
aura [55], which has been demonstrated to be often associated to endometriosis [56]. Both 
treatments were equally effective in decreasing endometriosis-related pain. After 6 months of 
treatment, the withdrawal rate was higher in the COC group (24.4% versus 11.3%), but the number 
of days with bleeding was higher in the DSG group (5.1 versus 3.2 days). The satisfaction rate was 
higher for patients receiving DSG (61.2% versus 37.8%), which showed also a significant 
improvement in QoL. In addition, the severity and number of migraine attacks were significantly 
different between baseline and the end of treatment in the DSG group (P<.001) but not in COC 
group (P=.078). Regarding available safety data on DSG as monotherapy for endometriosis, this 
latter trial demonstrated that among 31 patients, the most common AEs were acne (3.2%), nausea 
(3.2%), breast pain (6.4% in the POP group) and weight gain (6.4%) [55]. 
 
3.4 Etonogestrel-subdermal implant 
ENG (11-Methylene-17α-ethynyl-18-methyl-19-nortestosterone) is the derivative active form of 
DSG (gonane, testosterone derivate). It is available as single-rod progestin contraceptive 
subdermally placed in the inner upper arm for long-acting (three years) reversible contraception in 
women. The implant consists of a 40 mm by 2 mm semi-rigid plastic (ethylene vinyl acetate) rod 
containing ENG at dose of 68 mg [57].  
3.4.1 Pharmacokinetic 
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ENG is initially slowly released from the subdermal implant at 60-70 mcg/day, decreasing to 35-45 
mcg/day at the end of the first year, to 30-40 mcg/day at the end of the second year, and then to 25-
30 mcg/day at the end of the third year. After 4 days from the application of the implant, ENG 
achieves the Cmax of 813 pg/ml. After 4-6 months, it reaches the steady state of 200 pg/ml that 
remains sufficient to prevent ovulation for three years. It has been demonstrated that the ENG 
plasmatic levels are 40% higher in women weighing < 50 kg [58]. This drug is approximately 32% 
bound to SHBG. The total body Cl of ENG is around 7.5 L/h, and it remains constant during the 
time. Thus, it can be assumed that there is no accumulation of steroid drug and that the decreased 
serum concentrations are caused only by a slight lowering in the release rate over time [59]. After 
implant removal, plasmatic ENG is not detectable within 1 week [58].  
3.4.2 Clinical efficacy and safety 
Few data are available on the use of the ENG-subdermal implant for the treatment of women with 
endometriosis (Table 2). In an uncontrolled open clinical trial, the ENG-subdermal implant efficacy 
was evaluated in 50 symptomatic women with surgically confirmed endometriosis. The authors 
reported an improvement of pain levels and a high satisfaction rate (80%). After a short follow-up 
(12 weeks), women had spotting (26%) and intermestrual bleeding (4%) [60].  
In a RTC, Walch et al. compared the efficacy of ENG-subdermal implant (n = 21 patients) to 
DMPA-SC (n = 20) for the treatment of pain related to endometriosis. After 6-months of treatment, 
the mean reduction in pain was 68% in the ENG subdermal implant group and 53% in the DMPA-
SC group. The overall degree of satisfied plus very satisfied subjects was almost identical in both 
groups (57% in the ENG-subdermal implant group versus 58% in the DMPA group), and, at 1-year 
follow-up, also the improvement in pain intensity was equivalent [61].  
Safety data from the trial by Walch et al demonstrated that the most common AEs in patients 
receiving ENG-subdermal implant were breast tenderness (24%) and libido decrease (24%). 
Moreover, there was a lower withdrawal rate in the ENG group (n=4, 19%) compared to the 
DMPA-SC group (n=7, 35%). The main cause of ENG-discontinuation was unbearable bleeding 
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irregularities (n=2, 50%) [61].  
The effect of ENG-subdermal implant on bone mineral density (BMD) is controversial: in a 
prospective study, in which it was compared to non-hormone-medicated intrauterine device (IUD), 
similar changes in BMD were demonstrated from baseline to the end of treatment. In particular, the 
clinically significant mean decrease of z-score -1 was not nearly reached at all the anatomical sites 
of the body measured in both groups [62]. In contrast, another group reported a significantly 
decrease of -5.90% (P<0.001) on forearm BMD after 18 months from ENG-subdermal implant 
insertion [63].  
 
3.5 Medroxyprogesterone acetate 
Medroxyprogesterone acetate (MPA, 6α-Methyl-17α-hydroxyprogesterone) is a synthetic derivative 
of 17-hydroxyprogesterone (pregnane, progesterone derivative). MPA is available as oral 
formulation or depot formulation, which can be administered intramuscularly (DMPA-M) [64] and 
subcutaneously (DMPA-SC) every 3 months [65]. This progestin has also anti-androgenic and 
strong anti-glucocorticoid effect (thirty times higher than either DNG or NETA) [66]. 
3.5.1 Pharmacokinetic 
MPA (10-15 mg) is rapidly absorbed from the gastrointestinal tract, and its Cmax is obtained within 
2-4 hours after oral administration. MPA is approximately 90% bound to serum proteins, with the 
exception of SHBG. MPA is extensively hydroxylated and conjugated in the liver via CYP3A4, and 
it is subsequently eliminated in the urine. Administered in multiple dose (10-15 mg three-times a 
day for 90 days), such as suggested for the treatment of endometriosis, its reported t1/2 is more than 
30 hours [67]. 
Following a single dose of DMPA-M (150 mg IM), MPA concentration increases for approximately 
3 weeks to reach a Cmax of 1-7 ng/mL. The concentrations of MPA decrease exponentially until 
becoming undetectable (<100 pg/mL) between 120 to 200 days following injection [68].   
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DMPA-SC releases constantly MPA, reaching a Cmax of 0.953 ng/mL after 2-14 days from the 
administration. Overall, mean MPA levels at days 91, 104 and 120 are 0.427, 0.367 and 0.327 
ng/mL, respectively. MPA mean AUC0–91 is 45.1 ng·day/mL. It has been shown that MPA 
concentrations remains above 0.2 ng/mL for at least 91 days [69]. 
3.5.2 Clinical efficacy and safety 
Since the 1970s, retrospective studies have suggested that oral MPA (30-50 mg/day) is effective in 
treating pain symptoms in women with endometriosis [70, 71, 72]. In two RCTs, Telimaa et al. 
demonstrated that the administration of MPA (100 mg/day) for 6 months is as effective as danazol 
in the treatment of pain both after diagnostic laparoscopy [73] and after surgical excision of 
endometriosis [74]. One prospective double-blind RCT, involving 48 women with surgical 
diagnosis of endometriosis, compared MPA (45 mg/day) with naferelin (400 µg intranasal) for 
treating pain. Patients were treated for 6 months and followed for 1 year. There was a significant 
reduction in the severity of pain symptoms during the study, without any significant difference 
between the study groups [75]. These findings are in contrast to a prospective, double-blind RCT 
involving 100 infertile women (only 25% of them had mild-severe pelvic pain) with a surgical 
diagnosis of endometriosis, which compared the efficacy of 3-month administration of MPA (50 
mg/day) with placebo [76]. 
From data extracted and analyzed from RTCs, a Cochrane review reported that MPA (100 mg 
daily) appears more effective in reducing all symptoms up to 12 months of follow-up (MD -0.70, 
95% CI -8.61 to -5.39; P < 0.00001) compared with placebo. Moreover, patients receiving MPA 
had more cases of acne and edema [77]. 
DMPA has been investigated in few clinical trials for the treatment of women with endometriosis 
(Table 2). In a RTC (80 women), Vercellini et al. compared DMPA-M (150 mg/3 months) to cyclic 
COC plus oral danazol (50 mg/day) for 1 year to treat endometriosis-related pelvic pain. 40 patients 
were allocated in each study arm. At the end of treatment, 72.5% of the women in the DMPA-M 
arm were satisfied or very satisfied compared with 57.5% in COC plus danazol arm (p=0.24). A 
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significant decrease in all symptoms scores was reported in both study arms without significant 
differences. The main AEs in the DMPA-M group were spotting (26%), bloating (25%) and weight 
gain (21%). In addition, the median time to return of regular menstrual flow in women who 
received DMPA-M was 7 months. In both arms, there was a significant reduction in high-density 
lipoprotein cholesterol [78]. 
A RCT compared a 3-years regimen of DMPA-M (150 mg/3 months) with the levonogestrel-
releasing intrauterine system (LNG-IUD) in 30 patients after conservative surgery for 
endometriosis. Both treatments were effective in the management of pain symptoms, and the only 
domains where no amelioration was observed were dyspareunia and urinary/bowel symptoms. At 
TVS, no recurrence of lesions was detected in both groups. The dropout rate was higher in the 
DMPA-M group (53% versus 13%), and the two most common causes of discontinuation among 
the eight patients that interrupted DMPA-M were prolonged vaginal spotting (n=3, 37.3%) and 
significant bone loss over the lumbar spine (n=2, 25%) [79]. 
In two large RTCs, Crosignani et al. and Schalff et al. compared DMPA-SC (104 mg/0.65 ml) with 
leuprolide acetate (given every 3 months for 6 months). At 12-months of follow-up, DMPA-SC was 
statistically equivalent to GnRH-a in reducing pain symptoms. Moreover, significant improvements 
in QoL occurred in both treatment groups [80, 81]. Interestingly, in the study by Crosignani et al. 
patients who received DMPA-SC reported a significant amelioration in their sexual relationship 
after 6 months of treatment [80].  
One of major sources of concerns regarding the continuous DMPA use is the breakthrough 
bleeding, the primary reason for its discontinuation among women using it for contraception [82]. 
Moreover, pooled analysis from three Phase III contraceptive trials demonstrated that the therapy 
with DMPA (SC and M) causes gained weight [83, 84]. A further concern on DMPA use is the loss 
of BMD, which may increase the risk of fracture [85]. For this reason, in 2004 the FDA published a 
‘black box warning’, suggesting physicians its administration only if the other methods were 
unsuitable or unacceptable, limiting the maximum use to 2 years [86].  
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Regarding data on safety of DMPA (SC and M) for the treatment of endometriosis from evaluable 
trials, among 282 patients, 49.3% had a drug-related AE. The most common AEs were 
breakthrough bleeding (n=39, 12.1%), nausea (n=29, 9.0%), headache (n=26, 8.0%) and bloating 
(n=25, 7.8%). Specifically for DMPA-SC, in the studies by Crosignani et al. and Schalff et al., after 
6 months of treatment, the patients receiving the depot progestin group showed significantly less 
BMD loss than those treated with leuprolide; anyway, BMD returned to pretreatment levels at 12 
months’ follow-up. Moreover, when compared to GnRH-a, DMPA-SC caused less 
hypoestrogenism-related symptoms, such as headache (3.3-7.7% versus 6.3-10.4%) and hot flushes 
(2.3-5.9% versus 11.1-16.8%), but more irregular bleeding, varying from light spotting to uterine 
hemorrhage (5.4-12.5% versus 0.7%). However, in these two studies the di continuation rate 
secondary to AEs was 2-5.4% in the DMPA-SC group and 1.4-6.7% in the leuprolide group [80, 
81].  
 
 
3.6 Dienogest 
Dienogest (DNG, 17α-Cyanomethyl-δ9-19-nortestosterone) is a fourth-generation selective 
progestin (estrane, testosterone derivate). It has minimal androgenic, estrogenic, glucocorticoid or 
mineralocorticoid activity [87].  
3.6.1 Pharmacokinetic 
After a single dose, DNG (2 mg) has high bioavailability (<90%) [88], reaching a mean Cmax of 
51.7 ng/mL within 1.0 h (range of 0.7-4 h). Its mean AUC0–24h is 503 ng·h/mL. 90% of DNG binds 
to albumin, whereas only 10% is present in plasma in the free form. The DNG t1/2 is 10.6 h with a 
mean Cl of 3.28 L/h. DNG has no relevant interaction with various hepatic binding globulins such 
as SHBG and corticosteroidbinding globuline (CBG) [66]. CYP 3A4 is the most widely used 
enzyme in the metabolic pathway of DNG. The excretion of DNG takes place mainly through the 
urine after glucuronide and sulfate conjugation and most of the metabolites are eliminated during 
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the first 24 hours [89]. After once daily multiple doses, the mean Cmax and AUC0–24h of DNG 
slightly increase, resulting after 14 days in 56.6 ng/mL and 613 ng·h/mL, respectively. Moreover, in 
case of multiple administrations, its mean t1/2 and total body Cl are approximately 11.0 h and 3.32 
L/h, respectively [90]. 
3.6.2 Clinical efficacy and safety 
Several RTCs have investigated the use of DNG for the treatment of endometriosis (Table 3) [91]. 
A systematic review showed that DNG (2 mg/day) is superior to placebo in reducing pelvic pain 
(27.4 versus 15.1 mm, P <.0001) and as effective as GnRH-a in controlling symptoms associated 
with endometriosis. Moreover, DNG is effective in reducing endometriotic lesions (11.4 ± 1.71-3.6 
± 0.95, P <.001) [92]. Concerning the use of DNG as maintenance therapy after GnRH-a to treat 
pelvic pain associated with endometriosis, Kitawaki et al., in a prospective nonrandomized clinical 
trial, showed that long-term administration of DNG following GnRH-a therapy prolongs the relief 
of pelvic pain while reducing the amount of irregular uterine bleeding [93]. 
In a 6-months double-blind multicenter RTC, DNG (2 mg/day) efficacy and safety were evaluated 
in 255 Chinese patients with laparoscopically diagnosed endometriosis. At baseline, they had an 
endometriosis-associated pelvic pain (EAPP) score ≥30 mm on a 0-100 mm visual analog scale 
(VAS). After the end of treatment, DNG obtained a higher mean reduction in EAPP score than 
placebo (-24.54 mm; 95% CI -29.93 to -19.15; p < 0.0001). Moreover, DNG was well tolerated, 
although the incidence of drug-related AEs was higher to that of patients receiving placebo (29.4% 
vs 10.1%), with intensity of AEs mild-to-moderate in most women. Anyway, the AE-related 
discontinuation rate for both groups was comparable (1.6% vs 0.8%) [94]. 
Morotti et al. investigated the DNG efficacy for the treatment of women with rectovaginal 
endometriosis who had persisting pain symptoms during the administration of NETA. In this 24-
weeks open-label prospective study, the authors evaluated the satisfaction of 25 patients after 6 
months of DNG treatment. DNG obtained better results than NETA both in terms of pain relief and 
in terms of QoL improvement, which were evaluated with the Endometriosis Health Profile-30 
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(EHP-30) and Female Sexual Function Index (FSFI) questionnaires. Moreover, the endometriotic 
nodules volume did not significantly change during treatment. More common AEs in the DNG 
group included headache (16.0%), nausea (8.0%), breast tenderness (4.0%) [95].  
DNG has also been used for the conservative treatment of bladder endometriosis [96]. In recent 
pilot study including six women with bladder endometriotic lesions, the administration of DNG (2 
mg/day) for 12 months improved pain symptoms. Furthermore, urinary symptoms disappeared in 
all the patients and there was a significant size decrease of bladder nodules at TVS after 3 and 12 
months of treatment [97]. In a prospective study, Leonardo-Pinto et al. evaluated the effectiveness 
of DNG for the treatment of 30 women with DIE. After 12 months, they achieved a significant 
improvement in dysmenorrhea (p<.0001), pelvic pain (p=.0007), dyspareunia (p=.0093), and 
intestinal pain (p < 0.0001), with pain score at VAS reduced at least equal or to less than three for 
all endometriosis-related symptoms. However, there was not a significant reduction in the volume 
of the lesions assessed by TVS [98]. 
Vercellini et al., through a before-after study design, compared NETA and DNG for the treatment 
of women with endometriosis. Both drugs caused pain relief and improvement of psychological 
status, sexual functioning, and health-related QoL of the patients. After 6 months, the proportion of 
satisfied plus very satisfied women was almost identical between the two study groups (71% in 
NETA group versus 72% in DNG group). After DNG implementation, the absolute risk reduction 
in the occurrence of any AE compared to NETA was 13.9% Thus, DNG was better tolerated than 
NETA, but the much higher cost limited its acceptance by the women [99]. Surprisingly, up to now 
no RCT compared DNG with COCs or other progestins, the first-line therapies most commonly 
used for the treatment of endometriosis [91]. 
A recent study has evaluated the safety and tolerability of DNG among patients with endometriosis-
associated pain by pooling data from four randomized, controlled, European studies. Overall, 332 
women were treated with DNG (2 mg/day) for study periods ranging between 12 weeks and 65 
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weeks. The most common drug-related AEs were headache, breast discomfort, depressed mood, 
and acne, occurring in 9.0%, 5.4%, 5.1%, and 5.1% of women, respectively [100].  
The effect of DNG on BMD is controversial. In a comparative study, Lee et al. administered DNG 
(2 mg/day) or GnRH-a plus add-back therapy (NETA 0.5 mg/day or E2 1 mg/day) for the treatment 
of endometriosis. The authors reported a decline in BMD at the lumbar spine in both treatment 
groups (−2.3 % for DNG and −2.5% for GnRH-a plus add-back) [101]. These results are in line 
with those reported by Momoeda et al. that showed a significantly decrease (−1.6 %) of lumbar 
spine BMD after 24 weeks of treatment with DNG in 135 patients with endometriosis [102]. In 
contrast, Strowitzki et al. and Lang et al. reported no or minimal changes in BMD (-0.10% and 
+0.25% at lumbar spine, respectively) following a 6-month treatment with DNG [94, 103].  
 
3.7 Levonorgestrel-releasing intrauterine device 
Levonogestrel (LNG, 17α-Ethynyl-18-methyl-19-nortestosterone) is a synthetic second-generation 
progestin chemically derived from 19-nortestosterone (gonane, testosterone derivate). It is six times 
more potent than progesterone, but also has strong androgenic properties. Most of the interest for 
LNG in the treatment of endometriosis is focused on the LNG-releasing intrauterine device (LNG-
IUD) [104]. 
3.7.1 Pharmacokinetic 
LNG-IUD (52 mg) releases low doses of LNG directly into the uterine cavity. Its initial release rate 
is approximately 20 µ/day over the first 3 months (day 0-90), it is reduced to approximately 18 
µ/day after 1 year and then decreases progressively to approximately 10 µ/day after 5 years [105]. 
A stable serum LNG concentration of approximately 150–200 pg/mL occurs after the first few 
weeks, following insertion of LNG-IUD [106]. LNG concentrations at 12-, 24- and 60 months have 
been estimated to be 180 pg/mL, 192 pg/mL, and 159 pg/mL, respectively. When released, LNG 
has a VD of approximately 1.8 L/kg, and it is about 98-99% bound to serum proteins (47.5% to 
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SHBG) [66]. The excretion of LNG and its phase I metabolites is primarily as glucuronide 
conjugates via urine in about 45% and via feces in about 32% of total [105]. 
3.7.2 Clinical efficacy and safety 
The most important mechanism of action of the LNG-IUD is through its local suppressive action on 
the endometrium. Amenorrhea develops in approximately 20% of LNG-IUD users by one year 
[105]. In patients with endometriosis, the LNG-IUD decreases the expression of glandular and 
stromal estrogen (α and β) and progesterone receptors in the ectopic endometrium and, thus, 
induces glandular atrophy and decidualization of the stroma [107, 108].  
A pilot-study including 11 women with symptoms caused by rectovaginal endometriosis 
demonstrated that the use of the LNG-IUD improved the severity of all pain symptoms, including 
deep dyspareunia and dyschezia, at 1-year follow-up. Moreover, the LNG-IUD succeeded in 
decreasing the rectovaginal lesions size, evaluated by transrectal ultrasound and TVS [109]. 
Several RTCs have investigated the use of LNG-IUD for the treatment of endometriosis (Table 4).  
Chwalisz et al. compared the efficacy of LNG-IUD and depot GnRH-a (leuprolide 3.75 mg) in 82 
women with endometriosis-related pain over a period of six months. At 6 months of follow-up, both 
treatments were similarly effective in improving chronic pelvic pain, demonstrating a six-point 
decrease from baseline in the VAS pain score. At the end of the study, 13% (n = 5) of patients in 
the LNG-IUD group and the 14% (n = 6) of those in the leuprolide group failed to reach a VAS 
pain score of less than three. Furthermore, no difference was observed between groups with 
reference to improvement in QoL [110]. In a meta-analysis including five RCTs, the comparative 
evaluation of LNG-IUD and GnRH-a demonstrated that both regimens succeed in reducing pain, as 
well as CA125 serum levels and the American Society of Reproductive Medicine staging scores. 
Irregular bleeding, simple ovarian cysts and one-sided lower abdominal pain occurred more 
commonly in patients receiving the LNG-IUD (P<.03), whereas those receiving GnRH-a 
experienced more hypo-estrogenic AEs (P<.05) [111]. 
The long-term therapy with LNG-IUD has been evaluated in a retrospective study by Lockhat et al., 
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in which it resulted efficacious in improving symptoms throughout a 3-year study period [112]. 
These results are in line with those obtained in a RCT that compared the 36-month use of LNG-IUD 
with DMPA-M in 30 patients with moderate and severe endometriosis. The mean pain score 
evaluated at VAS was significantly reduced by the next visit at three months after insertion of 
LNG-IUS (P <.02) or starting of DMPA-M injection (P <.002), and the effect was maintained all 
through the study period as long as the therapy was continued. Anyway, there was no significant 
specific change in dyspareunia and urinary and bowel symptoms in both groups of patients [79]. 
The LNG-IUD has been used for the post-surgical prevention of endometrioma recurrence. In their 
randomized prospective studies, Tanmahasamut et al. and Wong et al. did not identify any 
endometrioma recurrence after 12 and 36 months of treatment with LNG-IUD, respectively [79, 
113]. In two retrospective studies, the postoperative LNG-IUD use was superior to COCs in 
preventing endometrioma recurrence [114, 115]. In contrast, a retrospective study reported a 
cumulative postoperative endometrioma recurrence rate of 25% after 5 years of treatment with 
LNG-IUD [116]. More recently, Kim et al. in a RTC demonstrated equivalent recurrence rate of 
endometrioma between women allocated in LNG-IUD group (10/40, 25%) and those in the 
expectant management group (15/40, 37.5%) at 30-months of follow-up. In both study groups, 
patients received an initial treatment, after laparoscopic cystectomy, with six cycles of GnRH-a. 
The number of recurrent endometrioma requiring a second surgery or a hormonal treatment was 
significantly higher in the expectant management group (8/40, 20% versus 1/40, 2.5%) [117]. 
Regarding the safety profile of LNG-IUD as post-surgical monotherapy for endometriosis, in the 
two largest RTC evaluable for drug-related AEs, among 48 patients, the most common were oily 
skin (n=20, 41.6%), weight gain (n=19, 39.5%), breast tenderness (n=18, 37.5%) and irregular 
bleeding (n=17, 35.4%) [113, 118]. 
 
4.0 Conclusion 
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Endometriosis, a chronic and recurrent disease, represents a challenge to health-care providers and a 
burden on the health care system. If COCs have been used for decades as the first-line treatment for 
endometriosis, progestins are increasingly and successfully employed as monotherapy. In fact, 
progestins as monotherapy induce decidualization and atrophy of implants and improvement of 
symptoms of patients with endometriosis, they are relatively well-tolerated and most of them are 
inexpensive. Further studies are required to compare the efficacy and tolerability of different types 
of progestins in the treatment of endometriosis. 
 
5.0 Expert opinion  
Currently, the medical choices for symptomatic endometriosis are based on patient preferences and 
treatment goals as well as the efficacy and the safety-profile, the desire of contraception, the cost, 
and the route of administration of the drugs. As endometriosis is a chronic and recurrent disorder, a 
long-term medical therapy should be well-tolerated, have only limited AEs and be cost-effective 
[26]. However, hormonal treatments do not eradicate the disease but allow to obtain an effective 
control of pain symptoms in the 80-90% of cases. In line with this, recurrence of symptoms is 
frequent after discontinuation of treatment [119]. While progestins can decrease the volume of 
endometriomas [36], there is no evidence that the medical therapy can prevent the progression of 
DIE. Therefore, patients undergoing long-term hormonal treatment for endometriosis-related pain 
need a follow-up by ultrasonography to timely detect the progression of DIE causing bowel or 
ureteral stenosis [120]. 
If COCs have been used for decades as the first-line treatment for symptomatic endometriosis, 
progestins are increasingly and successfully employed as monotherapy [10]. These drugs are often 
started empirically without a surgical diagnosis of endometriosis and are particular efficacious in 
women suffering dysmenorrhea and menstrual-related symptoms.  
Progestins cause a lower increase in the thrombotic risk compared with COCs and are better 
tolerated by patients suffering migraine [121]. A potential disadvantage for the use of progestins in 
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women desiring contraception is that only three of them (DSG, ENG-subdermal implant and LNG-
IUD) are approved as contraceptive. Overall, medical therapy with progestins enables satisfactory 
long-term pain control in around two-thirds of symptomatic women [2]. The imbalance of ER and 
PR subtypes or of adhesion molecules imbalance might contribute to the mechanisms involved in 
the progesterone resistance of patients’ population refractory to these hormonal therapies. As no 
biomarkers for progestin resistance has been proposed, a dynamic monitoring of response to 
progestins is warranted in order to switch to other options or to discuss in the appropriate time the 
surgical option [122]. 
There is lack of data on the specific effects of progestins use on the breast, the mood and 
cardiovascular system. A French report on contraception with progestins showed that it has never 
been demonstrated that their use is associated with an increased risk of breast cancer. Moreover, 
there is no evidence for considering the progestin-only contraception as a risk factor for fractures. 
Also, the impact of long-term systemic progestins use on BMD is controversial [27].  
Data from clinical trials for the treatment of endometriosis suggested that progestins are well 
tolerated when administered in a long-term treatment. Data from clinical trials suggest that the most 
frequent AEs reported by the patients are spotting and breakthrough bleeding, weight gain, breast 
tenderness and depression [17, 18]. These AEs are also the major cause of discontinuation of 
treatment. 
Currently, randomized, controlled studies support the use of oral progestin-only treatment for 
controlling pelvic pain associated with endometriosis. Almost none of these trials is double-blinded. 
A Cochrane review [77] published in 2012 including 13 RCTs evaluated the use of progestins 
versus placebo, danazol, oral/sub-dermal contraceptives, GnRH-a and other drugs used in the 
treatment of endometriosis-related pain. When progestins were compared with placebo discordant 
results emerged: only MPA (100 mg daily) appeared to be more effective in reducing all symptoms-
related to endometriosis compared with placebo. Furthermore, data showed that patients treated 
with progestins experienced more frequently bleeding or amenorrhea than those who received other 
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drugs. A new systematic review with meta-analysis is required in order to include the most recent 
studies on progestins for treating endometriosis-related pain.  
It is well known that progestins can induce decidualization and eventual atrophy of endometriotic 
implants and that they improve women’ pain, but there is a common misconception that all 
progestins have similar mechanisms of action and PK parameters. Moreover, it is growing the 
evidence that progestins, in addition to their systemic effect on estrogen production, may also exert 
an immune-suppressive influence on endometriotic lesions at local disease sites [23] and 
furthermore that this influence is not uniform for all progestins, depending from the biological 
activity. 
In fact, each one has a distinct biological effect influenced by pharmacodynamics affinity not only 
for PR, but also for other steroid receptors, such as estrogen, androgen, and glucocorticoid. 
Moreover, progestins have different route of administration. Most of the available information in 
literature on the PK of progestins arise from their use as oral contraceptives, often in combination 
with estrogens. Furthermore, most of the PK studies are focused on their single-dose administration, 
thus, before achieving the steady-state, which likely correlates with the biological activity of the 
steroid. In view of their long t1/2, steady-state will not be reached before 5-10 days of therapy. At 
least, there are wide PK variations between patients, probably due to genetic factors and 
environmental factors. Thus, specific PK data on progestins alone are needed. Overall, knowledge 
of synthetic progestogens is far to be complete and the situation is further complicated by the 
multiplicity of biological effects produced by these steroids in human.  
The two progestins supported by the largest available evidence in treatment endometriosis are 
NETA and DNG.  
Although FDA licensed oral NETA at 5 mg/day, several studies reported excellent outcomes using 
only 2.5 mg/day. Its lower dosage increases tolerability, reducing AEs, and limits the negative 
impact on serum cholesterol values. NETA exerts directly an activity on estrogen receptors -α and -
β, and it is a substrate for aromatase, being converted in the liver to a small extent (0.20–0.33%) to 
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potent EE [32]. For these reasons, unlike most other progestins, NETA has some estrogenic 
activity, which may be responsible for a positive effect on BMD. NETA is efficacious in the long-
term control of endometriosis-related pain [37]; however, being not able to induce a significant 
regression of implants, it does not represent a definitive curative treatment for this disease.  
DNG is a new fourth-generation selective progestin. As reported in several clinical trials, DNG 
showed efficacy and good tolerability at doses of 2-4 mg/ day in continuous administration for 3-24 
months in patients with endometriosis. Although DNG seems to be at least equally effective and 
better tolerated than NETA [95, 99], the much higher cost limits its acceptance by patients. A recent 
review evaluated the PK characteristics of DNG with other progestins derivatives, such as NETA, 
LNG and gestodene. This comparison showed that DNG is one of few synthetic progestogens that 
does not bind to SHBG, that has no influence on the PK of testosterone and has no androgenic 
effects. Moreover, DNG has the highest free-unbounded fraction in the plasma (approximately 
10%). The high circulating levels of free DNG explain the wide penetration of the molecule in 
several tissues [66]. 
An innovative approach to improve the use of progestins in endometriosis is the development of 
long-acting progestogen systems. In the Cochrane review [77], it has been reported the absence of 
benefit after depot administration of progestins versus other treatments (low dose COCs or 
leuprolide acetate). Anyway, only two comparative trials on DMPA were included in this review, 
and, further studies are needed to draw a definitive conclusion. One of major sources of concerns 
regarding continuous DMPA use is the decrease of BMD. However, the reversibility of the negative 
impact of DMPA on BMD toward or to baseline values within 2 years after discontinuation has 
been demonstrated in several studies [123, 124, 125] and the data regarding the risk of an eventual 
fracture are controversial [126, 127, 128]. Furthermore, DMPA is often accompanied by 
unintentional weight gain, loss of libido, which might adversely affect a woman's QoL and preclude 
long-term use. Among long-acting progestogen systems, ENG-subdermal implant could be 
preferable to DMPA in patients with preexisting high BMI and impaired metabolic profiles for its 
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lower impact on metabolic profile. Furthermore, the ENG-subdermal implant is particularly useful 
for patients desiring contraception. The main disadvantage of the depot formulation is the 
impossibility to interrupt treatment in the event of AEs. In fact, in some patients, the irregular 
bleeding caused by depot progestins may be prolonged, repeated and difficult to correct. 
One of the best candidates for the long-term treatment of endometriosis is the LNG-IUD. In 
comparison with systemic administration, the local release of a drug should theoretically provide a 
similar or improved efficacy, particularly evident on the local target organ, with reduced systemic 
AEs. LNG-IUD is particularly suitable for patients with concomitant adenomyosis [129], and who 
do not want to conceive or wish to postpone pregnancy, whose main symptom is dysmenorrhea, and 
who do not tolerate progestins administered systemically. Moreover, the LNG-IUD can be inserted 
at the end of a surgical procedure as a postoperative adjuvant treatment for endometriosis. The 
results from several RCTs support the use of LNG-IUD with the aim to improve pain. Importantly, 
the LNG-IUD abolishes or reduces menstruations in the large proportion of women, but it does not 
inhibit ovulation except for a few months after insertion, raising concerns for the risk of 
endometrioma recurrence, in line with the theory of endometriomas originating from corpus luteum 
[130]. Anyway, controversial results of LNG-IUD efficacy on this topic have been reported. 
Future double-blinded studies should compare the efficacy and tolerability of different progestins in 
the long-term treatment of endometriosis-related pain. Population should be select in relation of 
specific phenotypes of endometriosis. Furthermore, since patients with endometriosis often require 
to be treated for years, multicentric prospective studies with large sample size should investigate the 
safety of progestins in the long-term use. 
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Table 1. Available formulations of progestins for the treatment of endometriosis 
 
Route of administration Drug Biological activities 
  Anti-
estrogenic 
Estrogenic Androgenic Anti-
androgenic 
Gluco-
corticoid 
Anti-
mineracorticoid 
Oral route NETA + + + - - - 
CPA + - ++ - + - 
MPA + - ± - + - 
DGS + - + - - - 
DNG ± ± - + - - 
Depot injection DMPA + - ± - + - 
Subdermal implant ETG + - + - - - 
Intrauterine device LNG-IUD + - + - - - 
 
(+) effective; (±) weakly effective; (−) not effective 
Ac
ce
pte
d M
an
us
cri
pt
NETA=norethindrone acetate, CPA=cyproterone acetate, MPA=medroxyprogesterone acetate, DMPA=depot medroxyprogesterone acetate, 
DGS=desogestrel, DNG=dienogest, ETG=etonogestrel, LNG-IUD=levonogestrel-intrauterine device 
 
 
Table 2. Studies investigating long-acting progestogen systems for the treatment of endometriosis 
 
Author, year Study design Population Regimen Follow-up Results AE 
Vercellini, 1996 
[78] 
Multicenter, 
prospective, 
randomized 
80 women with 
confirmed diagnosis of 
endometriosis 
DMPA-M (150 
mg) every 3 
months or COC 
(ethinyl estradiol 
0.02 mg, 
desogestrel 0.15 
mg) plus 
danazol (50 mg) 
for 21 days of 
each 28-day 
cycle 
12 months Similar pain relief 
at VAS in both 
groups 
DMPA-M group: 
spotting (26%), 
bloating (25%), 
weight gain (21%); 
COC plus danazol 
group: weight gain 
(30%), bloating 
(28%), headache 
(23%) 
 
Ponpuckdee, 2005 
[60] 
Single center, 
prospective 
50 women with 
recurrent pain after 
surgical treatment 
ENG-subdermal 
implant (68 mg) 
12 weeks Improvement of 
pain at VAS 
(P<.001) and 
menstrual 
symptoms (P<.001) 
Spotting (26%), 
intermenstrual 
bleeding (4%) 
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Crosignani, 2006 
[80] 
Multicenter, 
prospective, 
randomized  
300 women with 
confirmed diagnosis of 
endometriosis 
DMPA-SC (104 
mg/0.65) or 
leuprolide (3.75 
or 11.25 mg 
depot IM) every 
3 months, for 6 
months 
18 months Similar pain relief 
in both groups 
(P<.001) 
DMPA-SC group: 
intermenstrual 
bleeding (12.5%), 
nausea (11.2%), hot 
flushes (5.9%); 
Leuprolide group: hot 
flushes (16.8%), 
nausea 7%), headache 
(6.3%); 
 
At 12-months, in 
DMPA-SC group 
smaller reductions in 
total hip and lumbar 
spine BMD than in 
leuprolide group (P< 
.001) 
 
Schlaff, 2006 [81] Multicenter, 
prospective, 
randomized 
274 women with 
confirmed diagnosis of 
endometriosis 
DMPA-SC (104 
mg/0.65) or 
leuprolide 
(11.25 mg depot 
IM) every 3 
months, for 6 
months 
12 months Similar pain relief 
in both groups 
(P<.001) 
DMPA-SC group: 
headache (7.7%), 
injection-site reaction 
(6.9%), intermenstrual 
bleeding (5.4%); 
Leuprolide group: hot 
flushes (11.1%), 
headache (6.3%), 
libido decrease 
(5.2%); 
 
At 6-months, In 
DMPA-SC group 
smaller reductions in 
BMD than in 
leuprolide group (P< 
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.001, P<.001) 
 
Walch, 2009 [61] Single center, 
prospective, 
randomized 
41 patients with 
confirmed diagnosis of 
endometriosis 
ENG-subdermal 
implant (68 mg) 
or DMPA-SC 
(104 mg/0.65) 
every 3 months 
 
1 year Different, but not 
statistically 
significant, 
improvement of 
pain: 68% in the 
ENG-subdermal 
implant group and 
53% in the DMPA–
M group (P.36) 
ENG-subdermal 
implant: breast 
tenderness (24%), 
libido decrease (24%), 
headache (14%); 
DMPA-SC group: 
libido decrease (30%), 
headache (20%), 
breast tenderness 
(15%) 
 
 
AE=adverse event, DMPA-M= Intramuscular depot medroxyprogesterone acetate, DMPA-SC= Subcutaneous depot medroxyprogesterone acetate, 
ENG=etonogestrel, VAS=visual analogue scale 
 
 
Table 3. Randomized comparative trials of dienogest for the treatment of endometriosis 
 
 
Author, year Population Regimen Follow-up Results AE 
Cosson, 2002 [131] 120 women with 
confirmed grade 2-4 
(rAFS) endometriosis, 
post-surgical treatment 
DNG (1 mg/day) or 
triptorelin (3.75 mg 
IM) every 4 weeks, for 
16 weeks 
12 months Similar modification in 
the implant rAFS score 
at second laparoscopy 
was  
 
Different, but not 
statistically significant, 
satisfaction to the 
treatment: 34.5% very 
satisfied and 51.7% 
satisfied in the DNG 
group, 30% very 
DNG group: 
intermenstrual bleeding 
(61.6%), hot flushes (9. 
6%); 
Leuprolide group: hot 
flushes (61.2%), 
intermenstrual bleeding 
(25.6%) 
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satisfied and 50% 
satisfied in the 
leuprolide group (P.39) 
Harada, 2009 [132] 171 patients with 
confirmed endometriosis 
DNG (2 mg/day) or 
buserelin (900 μg/day, 
intranasally) every 4 
weeks 
6 months Similar pain relief and 
improvement of QoL in 
both groups 
DNG group: 
intermenstrual bleeding 
(95%), hot flushes (50%); 
headache (25%); 
Leuprolide group: 
intermenstrual bleeding 
(67%), hot flushes (67%); 
headache (34%) 
 
Strowitzki, 2010 
[133] 
252 patients with 
confirmed endometriosis 
DNG (2 mg/day) or 
leuprolide (3.5 mg 
depot IM) every 4 
weeks, for 24 weeks 
6 months Similar pain relief at 
VAS in both groups 
(P=.0004); more 
improvement of QoL in 
DNG group 
DNG group: headache 
(12.5%), weight gain 
(6.7%), depression (5.0 
%);  
Leuprolide group: 
headache (19.5%), 
depression (8.6%),  
sleep disorder (7.8%) 
 
 
 
Changes in mean lumbar 
BMD +0.25% with DNG 
and –4.04% with LA 
subgroups (P = .0003) 
 
Lee, 2016 [101] 64 women with 
confirmed endometriosis, 
post-surgical treatment  
DNG (2 mg/day) or 
leuprolide (3.75 mg 
depot SC) plus add-
back therapy (1.0 
mg/day of E2 and 0.5 
mg/day of NETA) 
No follow-up Visual analogue scale 
pain score decreased 
significantly in both 
groups  
DNG group: 
intermenstrual bleeding 
(53.8-55.6%), hot flushes 
(11.1%); depression 
(11.1%); 
Leuprolide plus add-back 
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every 4 weeks, for 24 
weeks 
therapy group: 
intermenstrual bleeding 
(0.8-22.2%), hot flushes 
(11.5%), genital dryness 
(11.5%) 
 
Significant decline BMD 
of the lumbar spine in 
both treatment groups (-
2.5 % for leuprolide plus 
add-back and -2.3 % 
 for DNG) 
 
Takaesu, 2016 
[134] 
111 women with 
confirmed endometriosis, 
post-surgical treatment  
DNG (2 mg/day) or 
goserelin (1.8 mg 
depot IM) every 4 
weeks, for 24 weeks 
24 months No significant 
difference in the 
postoperative 
recurrence rate in both 
groups;  
 
Menstrual pain and 
chronic pelvic pain 
were significantly 
improved in both 
groups 
DNG group: 
intermenstrual bleeding 
(100%), hot flushes 
(11%); headache (9%); 
Goserelin group: hot 
flushes (94%); 
intermenstrual bleeding 
(6%), headache (4%); 
 
 
 
 
AE=adverse event, rAFS=according to the Revised American Fertility Society, QoL=quality of life, DNG=dienogest, VAS=visual analogue scale, 
IM=intramuscular, SC= subcutaneous, E2=estradiol, NETA=norethindrone 
 
 
Table 4. Randomized comparative trials of levonorgestrel-intrauterine device for the prevention of the treatment of endometriosis 
 
Author, year Population Regimen Follow-up Results AE 
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Petta, 2005 [135] 82 women with confirmed 
endometriosis 
LNG-IUD or 
leuprolide (3.75 mg 
depot IM) every 28 
days 
 
6 months Chronic pelvic pain 
decreased significantly in 
both groups;  
LNG-IUD group: 
intermenstrual 
bleeding (71%); 
Leuprolide group: 
intermenstrual 
bleeding (34%)  
Gomes, 2007 [136] 22 patients with 
confirmed endometriosis 
LNG-IUD or 
leuprolide (3.75 mg 
depot IM) 
6 months Pain score were 
significantly reduced in 
both groups. 
 
NR 
Wong, 2010 [79] 30 women with confirmed 
endometriosis, post-
surgical treatment 
LNG-IUD or DMPA 
every 28 days 
 
36 months Pain score were 
significantly reduced in 
both groups; 
 
No significant difference 
in the postoperative 
recurrence rate in both 
groups. 
Irregular vaginal 
bleeding was a 
common observation 
in both groups, but 
the severity and 
frequency were 
worse in the DMPA 
group 
 
Significantly higher 
mean DEXA T-score 
over the lumbar spine 
in the LNG-IUD 
group compared with 
DMPA Group 
Ferreira, 2010 [137] 44 women with confirmed 
endometriosis 
LNG-IUD or 
leuprolide (3.75 mg 
6 months Significant reduction in 
pain score with no 
NR 
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depot IM) every 28 
days 
 
significant difference in 
both groups 
Bayoglu Tekin, 2011 [118] 40 women with confirmed 
severe endometriosis 
LNG-IUD or 
goserelin (3.75 mg 
depot SC) every 28 
days 
 
36 weeks TEPS decreased in the 
LNG-IUD group at 1, 3, 
and 6 months follow-up 
visits, but at 12 months 
of follow-up TESP 
scores were increased to 
values similar to 
pretreatment values. 
Goserelin group showed 
a significant decrease in 
the VAS score and TEPS 
at the end of 1 year; 
 
The patients in the LNG-
IUD group showed a 
lower satisfaction to the 
treatment than in the 
goserelin group. 
LNG-IUD group: 
intermenstrual 
bleeding (71%); 
simple ovarian cysts 
(55%), One-sided 
lower abdominal 
pain (40%); 
 
Goserelin group:  
Vasomotor 
symptoms (55%), 
amenorrhea (30%),  
weight gain (5%)  
Tanmahasamut, 2012 
[113] 
55 women with confirmed 
endometriosis, post-
surgical treatment 
LNG-IUD or 
expectant 
management  
12 months In the LNG-IUD group 
there was a greater 
reduction in 
dysmenorrhea (P=.006), 
pelvic pain (P=.038) 
VAS but a comparable 
reduction in dyspareunia 
VAS (P=.831) 
LNG-IUD group: 
intermenstrual 
bleeding (37%), acne 
(59.3%), oily skin 
(74.1%); 
Expectant 
management group: 
intermenstrual 
bleeding (69.6%) 
acne (56.5%), oily 
skin (69.6%) 
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Chen, 2017 [117] 80 patients with 
endometriomas 
undergoing laparoscopic 
cystectomy  
LNG-IUD plus 
leuprolide (3.75 mg 
depot IM) every 28 
days or leuprolide 
(3.75 mg depot IM) 
every 28 days plus  
 
30 months Endometrioma 
recurrence did not 
significantly differ in 
both groups;  
 
lower dysmenorrhea 
recurrence and higher the 
dysmenorrhea VAS 
reduction in the LNG-
IUD plus leuprolide 
group 
LNG-IUD plus  
Leuprolide group: 
intermenstrual 
bleeding (69.6%) 
acne (56.5%), oily 
skin (69.6%) 
leuprolide group: 
breast tenderness 
(37.5%), headache 
(32.5%), vaginal 
spotting (27.5%); 
 
 
AE=adverse event, LNG-IUD=levonorgestrel-intrauterine device, VAS=visual analogue scale, IM=intramuscular, SC= subcutaneous, NR=not 
reported, DEXA= dual-energy x-ray absorptiometry, TESP= total endometriosis severity profile score 
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Figure 1. Progestins reduce the frequency and increase the amplitude of gonadotropin-
releasing hormone (GnRH) pulsatile release, decreasing the secretion of follicle stimulating 
hormone (FSH) and luteinizing hormone (LH). They lead to suppress the ovarian 
steroidogenesis with consequent anovulation and low serum levels of endogenous ovarian 
steroids. Moreover, progestins have anti-inflammatory effect, and directly act on ectopic 
endometrial cells, reducing the expression of matrix metalloproteinases. All these effects 
reduce the implantation and progression of endometriotic lesions. 
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Figure 2. Besides the natural progestin, progesterone, there are different classes of progestins. 
The main progestins used in treatment of endometriosis belong progesterone derivatives 
(pregnanes), testosterone derivatives (estranes and gonanes) and spironolactone derivatives. 
